Middle East and Africa Insulin Delivery Devices Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Middle East and Africa Insulin Delivery Devices Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The Middle East and Africa Insulin Delivery Devices Market is expected to register a CAGR of more than 3.2% over the forecast period.

The COVID-19 pandemic has substantially impacted the Middle East and Africa Insulin Delivery Devices Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of Insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. Novo Nordisk stated on their website that “Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.” Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin delivery devices.

An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose levels, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps. This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.

Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate administration of insulin. In 2021, Medtronic launched an Extended infusion set that leverages advanced materials that help reduce insulin preservative loss and maintains insulin flow and stability. The set is compatible with all MiniMed 600 and 700 series insulin pumps. The new tubing connector improves the physical and chemical stability of insulin, reliability of infusion site performance, and reduces the risk of infusion set occlusion. In addition to the new infusion set, the Medtronic Extended reservoir is also tested and approved to keep insulin stable and safely used for up to 7 days.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsIncreasing diabetes prevalence

The diabetes population in the Middle East and African region is expected to rise by more than 3.5% during the forecast period.

The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of insulin.

According to IDF, 73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.

In the Middle East and African region, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Governments in the ME have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Middle East and African region.

Iran is expected to dominate the Middle East and Africa Insulin Delivery Devices Market

In 2021, Iran held the largest share in the Insulin Delivery Devices market in the Middle East and African region. Iran is expected to register a CAGR of over 4% between 2022 and 2027.

Diabetes is a serious public health concern in Iran, the Middle East's second-largest country, due to its high prevalence rate, growing occurrence rate, and economic impact. It is estimated that by the year 2030, 9.2 million Iranian individuals will have diabetes. Diabetes-related mortality in Iran continues to rise; the age-standardized death rate from diabetes has risen throughout the years. Diabetes has significant economic consequences in the country. Diabetes, in addition to its high direct health-care costs, is a significant risk factor for other chronic illnesses such as cardiovascular disease.

Diabetes complications, for example, accounted for USD 412 (49%) of the USD 843 per capita cost of diabetes. Yazd, a world heritage city located in the center of Iran, has one of the highest recorded prevalences of DM in Iran. Other cities in Iran have varying levels of DM awareness. For example, in Kerman, a province south of Yazd, the prevalence of undiagnosed diabetes is only 2.7%, but it is 25% in northern Iran. Despite the widespread availability of drugs and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia, and hypertension (particularly among young men and women) remains inadequate.

However, the roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the market.

Competitive Landscape

The Middle East and Africa Insulin Delivery Devices market is consolidated in nature due to the presence of only a few major companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Novo Nordisk, Sanofi, Eli Lily and Company, Medtronic, Insulet, Ypsomped, Becton Dickinson and Company, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.